Published online before print October 2, 2008

This Article Full Text Full Text (PDF) All Versions of this Article: jmoldx.2008.080105v1 10/6/493    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Riely, G. J. Articles by Ladanyi, M. Search for Related Content PubMed PubMed Citation Articles by Riely, G. J. Articles by Ladanyi, M.

Journal of Molecular Diagnostics 2008, Vol. 10, No. 6
Copyright © 2008 American Society for Investigative Pathology & Association for Molecular Pathology
DOI: 10.2353/jmoldx.2008.080105

Commentary

KRAS Mutations

An Old Oncogene Becomes a New Predictive Biomarker

Gregory J. Riely^* and Marc Ladanyi

From the Thoracic Oncology Service, Department of Medicine, * Department of Pathology and Human Oncology & Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York

Abstract

This commentary highlights a novel assay for detection of mutations in KRAS, which have recently emerged as a useful negative predictive biomarker.

This article has been cited by other articles:

				J. M. Brannan, W. Dong, L. Prudkin, C. Behrens, R. Lotan, B. N. Bekele, I. Wistuba, and F. M. Johnson Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2009; 15(13): 4423 - 4430. [Abstract] [Full Text] [PDF]

				R. M. Giusti, M. H. Cohen, P. Keegan, and R. Pazdur FDA Review of a Panitumumab (VectibixTM) Clinical Trial for First-Line Treatment of Metastatic Colorectal Cancer Oncologist, March 1, 2009; 14(3): 284 - 290. [Abstract] [Full Text] [PDF]